Jomed's Rising Star

Over the past three years, Jomed's sales growth has been dramatic, as the company has challenged market leaders like Guidant and AVE in the European stent marketplace. But, unlike other small cardiovascular start-ups, Jomed won't be content with a strong stent business--it is actively engaged in building a broad-based cardiovascular business that is truly global..

by David Cassak

Admittedly, the medical device industry is never likely to equal the number of companies that went public in 1996, when...

More from Business Strategy

More from In Vivo

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By 

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.